Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism

Bersano, Anna; Aghemo, Alessio; Rumi, Maria Grazia; Ballabio, E.; Candelise, Livia; Colombo, Massimo

doi:10.1016/j.ejim.2007.10.003

Cited by 26 publications

(20 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased metabolic activity in the basal ganglia of Parkinson's disease patients can be reversed by the administration of levodopa (Feigin et al, 2001). Of note, IFN-a has been associated with the development of Parkinson-like symptoms that were relieved by levodopa administration (Bersano et al, 2008). Using fMRI, typhoid vaccination was also found to alter activation in the basal ganglia.…”

Section: Basal Gangliamentioning

confidence: 99%

Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior

Haroon

Raison

Miller

2011

Neuropsychopharmacol

819

596

View full text Add to dashboard Cite

The potential contribution of chronic inflammation to the development of neuropsychiatric disorders such as major depression has received increasing attention. Elevated biomarkers of inflammation, including inflammatory cytokines and acute-phase proteins, have been found in depressed patients, and administration of inflammatory stimuli has been associated with the development of depressive symptoms. Data also have demonstrated that inflammatory cytokines can interact with multiple pathways known to be involved in the development of depression, including monoamine metabolism, neuroendocrine function, synaptic plasticity, and neurocircuits relevant to mood regulation. Further understanding of mechanisms by which cytokines alter behavior have revealed a host of pharmacologic targets that may be unique to the impact of inflammation on behavior and may be especially relevant to the treatment and prevention of depression in patients with evidence of increased inflammation. Such targets include the inflammatory signaling pathways cyclooxygenase, p38 mitogen-activated protein kinase, and nuclear factor-kB, as well as the metabolic enzyme, indoleamine-2,3-dioxygenase, which breaks down tryptophan into kynurenine. Other targets include the cytokines themselves in addition to chemokines, which attract inflammatory cells from the periphery to the brain. Psychosocial stress, diet, obesity, a leaky gut, and an imbalance between regulatory and pro-inflammatory T cells also contribute to inflammation and may serve as a focus for preventative strategies relevant to both the development of depression and its recurrence. Taken together, identification of mechanisms by which cytokines influence behavior may reveal a panoply of personalized treatment options that target the unique contributions of the immune system to depression.

show abstract

Section: Basal Gangliamentioning

confidence: 99%

Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior

Haroon

Raison

Miller

2011

Neuropsychopharmacol

819

596

View full text Add to dashboard Cite

show abstract

“…Indeed, administration of L-DOPA has been shown to reduce glucose metabolism in Parkinson's disease, notably in the putamen, in association with improvement in symptoms (Feigin et al, 2001). Of relevance in this regard, there is a case report of an IFN-α-treated patient who developed Parkinson-like symptoms that were relieved by L-DOPA (Bersano et al, 2008). These data suggest that administration of inflammatory stimuli like IFN-α leads to a state of decreased dopamine function that in turn results in changes in metabolic activity in relevant basal ganglia nuclei similar to that seen in Parkinson's disease.…”

Section: Inflammation Effects On Neurocircuitrymentioning

confidence: 99%

Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation

Miller

Haroon

Felger

2016

Neuropsychopharmacol

118

124

View full text Add to dashboard Cite

A wealth of data has been amassed that details a complex, yet accessible, series of pathways by which the immune system, notably inflammation, can influence the brain and behavior. These data have opened the window to a diverse array of novel targets whose potential efficacy is tied to specific neurotransmitters and neurocircuits as well as specific behaviors. What is clear is that the impact of inflammation on the brain cuts across psychiatric disorders and engages dopaminergic and glutamatergic pathways that regulate motivation and motor activity as well as the sensitivity to threat. Given the ability to identify patient populations with increased inflammation, the precision of interventions can be further tuned, in conjunction with the ability to establish target engagement in the brain through the use of multiple neuroimaging strategies. After a brief overview of the mechanisms by which inflammation affects the brain and behavior, this review examines the extant literature on the efficacy of anti-inflammatory treatments, while forging guidelines for future intelligent clinical trial design. An examination of the most promising therapeutic strategies is also provided, along with some of the most exciting clinical trials that are currently being planned or underway.

show abstract

“…The association between IFN-α use and Parkinsonism was first described by Mizoi et al 12 in 1997. Subsequent reports have shown that this complication can also result from treatment with Peg-IFN 15 . Here, we describe the first case of Peg-IFN-induced Parkinsonism in Brazil.…”

Section: Discussionmentioning

confidence: 94%

“…Data in the literature suggest that the average time for the appearance of Parkinsonism symptoms is variable and can be as long as 30 weeks after the initiation of therapy with interferon [12][13][14][15] . In all reported cases, the Parkinsonism symptoms persisted after discontinuation of interferon and there was partial improvement after treatment with levodopa, indicating a need for continued pharmacological treatment, as in our case.…”

Section: Discussionmentioning

confidence: 99%

“…The use of interferon has been associated with many neuropsychiatric complications, such as fatigue, confusional state, seizures, depression and even risk of suicidal ideation 8,9 . In recent years, it has emerged that patients treated with IFN-α or Peg-IFN can present rare neurological motor complications, such as dystonia, myorhythmia, chorea and Parkinsonism syndrome [9][10][11][12][13][14][15] . There have been few reported cases of Parkinsonism in hepatitis C patients treated with interferon, and there is therefore a need to clarify the treatment options in such cases.…”

mentioning

confidence: 99%

See 1 more Smart Citation